JP2022522914A5 - - Google Patents

Info

Publication number
JP2022522914A5
JP2022522914A5 JP2021510533A JP2021510533A JP2022522914A5 JP 2022522914 A5 JP2022522914 A5 JP 2022522914A5 JP 2021510533 A JP2021510533 A JP 2021510533A JP 2021510533 A JP2021510533 A JP 2021510533A JP 2022522914 A5 JP2022522914 A5 JP 2022522914A5
Authority
JP
Japan
Prior art keywords
patient
agent
cell
cells
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522914A (ja
Filing date
Publication date
Priority claimed from GBGB1807050.8A external-priority patent/GB201807050D0/en
Application filed filed Critical
Publication of JP2022522914A publication Critical patent/JP2022522914A/ja
Publication of JP2022522914A5 publication Critical patent/JP2022522914A5/ja
Pending legal-status Critical Current

Links

JP2021510533A 2018-04-30 2019-04-30 医学的使用 Pending JP2022522914A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1807050.8 2018-04-30
GBGB1807050.8A GB201807050D0 (en) 2018-04-30 2018-04-30 Medical uses
PCT/EP2019/061122 WO2019211310A1 (en) 2018-04-30 2019-04-30 Medical uses

Publications (2)

Publication Number Publication Date
JP2022522914A JP2022522914A (ja) 2022-04-21
JP2022522914A5 true JP2022522914A5 (https=) 2022-05-12

Family

ID=62494975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510533A Pending JP2022522914A (ja) 2018-04-30 2019-04-30 医学的使用

Country Status (10)

Country Link
US (1) US20210186977A1 (https=)
EP (1) EP3787685A1 (https=)
JP (1) JP2022522914A (https=)
KR (1) KR102908831B1 (https=)
CN (1) CN112399858A (https=)
AU (1) AU2019264457B2 (https=)
BR (1) BR112020022062A2 (https=)
CA (1) CA3097379A1 (https=)
GB (1) GB201807050D0 (https=)
WO (1) WO2019211310A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176743A1 (en) * 2005-07-29 2009-07-09 Priscilla Schaffer Methods for treating or preventing reactivation of a latent herpesvirus infection
CN101506154B (zh) * 2006-08-21 2015-06-17 辛塔制药公司 用于治疗增生性疾病的化合物
US20090123442A1 (en) * 2007-11-09 2009-05-14 Avaris Ab Expanded nk cells
CN102428173B (zh) 2009-03-26 2014-07-30 细胞维护北欧制药公司 Nk细胞的扩增
EP3184109B1 (en) * 2009-12-29 2020-11-18 Gamida-Cell Ltd. Methods for enhancing natural killer cell proliferation and activity
JP5989016B2 (ja) * 2011-06-24 2016-09-07 国立大学法人九州大学 Nk細胞の増幅方法
EP2877164B1 (en) * 2012-07-24 2023-07-05 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds
JP6797803B2 (ja) * 2014-12-31 2020-12-09 セルジーン コーポレイション ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法
KR102416781B1 (ko) * 2015-08-20 2022-07-05 고려대학교 산학협력단 수두 대상포진 바이러스에 의해 유발되는 질병의 치료 또는 예방용 약학 조성물

Similar Documents

Publication Publication Date Title
US12522570B2 (en) Toll like receptor modulator compounds
JP3140021B2 (ja) Tnf阻害剤含有医薬組成物
EP3507288B1 (en) 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
US9358233B2 (en) Method for treating acute myeloid leukemia
Riese et al. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes
AU2006320162B2 (en) Use of high-dose oxazaphosphorine drugs for treating immune disorders
ES3036762T3 (en) A modulatable switch for selection of donor modified cells
Tanasescu et al. Advances in the treatment of relapsing-remitting multiple sclerosis
US20080032989A1 (en) Method of treating inflammatory diseases using tyroskine kinase inhibitors
JP2020528455A5 (https=)
CN112804994A (zh) 治疗骨髓增殖性肿瘤的方法
Gold et al. Neuroprotection in Demyelinating Diseases
Li et al. Haploidentical transplantation with modified post-transplantation cyclophosphamide for patients with primary aplastic anemia: a multicenter experience
JP2013511975A5 (https=)
EP4424316B1 (en) Antitumor pharmaceutical composition comprising azvudine and chemotherapeutic agent
JP2022522914A5 (https=)
US20120196825A1 (en) Compositions and methods for modulating the immune system
AU2014295018A1 (en) Volasertib in combination with Decitabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome
JP2022522914A (ja) 医学的使用
AU2014295019A1 (en) Volasertib in combination with Azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome II
Khaidarov et al. PHARMACOLOGICAL OVERVIEW OF ACYCLOVIR
Nadeem et al. Treatment of Multiple Sclerosis
CA1332222C (en) Pharmaceutical composition for preventing and treating diseases caused by primary immune deficiences
CN116157126A (zh) 固有免疫激活药物及其用途
WO2023116397A1 (zh) 固有免疫激活药物及其用途